Want to see PBYI full AI Analyst Report?
PBYI Stock Chart & Stats
$7.98
$0.15(1.88%)
At close: 4:00 PM EDT
$7.98
$0.15(1.88%)
Day’s Range― - ―
52-Week Range$4.30 - $9.51
Previous CloseN/A
Volume23.96K
Average Volume (3M)562.57K
Market Cap
$476.97M
Enterprise Value$337.47
Total Cash (Recent Filing)$93.90M
Total Debt (Recent Filing)$4.82M
Price to Earnings (P/E)17.2
Beta1.15
Next Earnings
Oct 29, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.54
Shares Outstanding51,620,068
10 Day Avg. Volume391,965
30 Day Avg. Volume562,573
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.28
Price to Sales (P/S)1.30
P/FCF Ratio7.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.00Price Target Upside-24.81% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.38
Revenue Forecast (FY)$226.00M
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength (debt-free, Cash Runway)Elimination of term debt and nearly $94M in cash materially reduces fixed financing obligations and increases strategic optionality. This bolsters the company's ability to fund clinical programs, commercial investments, and absorb operational variability without near-term refinancing risk.
High Gross Margin And Returning ProfitabilitySustained ~75% gross margin and a return to GAAP profitability provide durable earnings leverage: high product-level margins support free cash flow generation and create a buffer versus commercial deductions, improving resilience across sales cycles.
Commercial Momentum And Raised GuidanceClear sequential and year-over-year demand improvement, plus raised full-year revenue guidance, indicates stronger commercial execution and adoption. Consistent prescription growth and distributor momentum support a steadier revenue base over the coming quarters.
Bears Say
High Gross-to-net Deductions (~28%)A nearly 28% gross-to-net rate meaningfully reduces realized revenue per unit and limits margin expansion. Because payer mix and rebates drive this metric, it can persist and structurally constrain net sales growth even if volumes rise, pressuring long-run revenue durability.
China Sublicense Royalty Reduction RiskA contractual royalty step-down tied to generic penetration creates a tangible downside to anticipated international royalty streams. If generics gain share, expected royalty cash flows could decline materially, reducing long-term revenue diversification and predictability.
Rising R&D And Higher Cash BurnPlanned meaningful R&D increases and a jump in quarterly cash burn elevate funding needs and shorten cash runway absent commensurate revenue growth. Higher investment is constructive long term but increases execution and financing risk over the next several quarters.
Puma Biotechnology News
PBYI FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was $4.30 and its highest was $9.51 in the past 12 months.
What is Puma Biotechnology’s market cap?
Puma Biotechnology’s market cap is $476.97M.
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Oct 29, 2026 which is in 66 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on Aug 06, 2026. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.12.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Overvalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is 0.09.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 51,620,068 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of $0.16 in its last earnings report, beating expectations of $0.04. Following the earnings report the stock price went up 9.729%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Currently, no hedge funds are holding shares in PBYI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Puma Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.00 (-24.81% Downside)
$6.00 (-24.81% Downside)
Blogger Sentiment
Bearish
PBYI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.12%
Trailing 12-Months
Company Description
Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
PBYI Company Deck
PBYI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum: meaningful QoQ and YoY increases in NERLYNX demand and bottle sales, a return to GAAP profitability in Q2, raised full-year revenue and net income guidance, and elimination of debt. These positives are tempered by pressure from high gross-to-net deductions (~28%), potential royalty reductions in China when generics gain share, rising R&D spend and increased quarter-over-quarter cash burn, and operational items like elevated DSO and a QoQ decline in new patient starts. On balance, the company appears to be in a strengthening commercial and financial position while managing identifiable near-term risks tied to deductions, international royalties, and increased investment in clinical programs.View all PBYI earnings summariesPBYI Stock 12 Month Forecast
Average Price Target
$6.00
▼(-24.81% Downside)
Technical Analysis
Heron Therapeutics
―
Voyager Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
15.86% Insiders
15.42% Mutual Funds
18.64% Other Institutional Investors
33.15% Public Companies and
Individual Investors